Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. reports developments in regenerative and cellular medicine, including longevity-focused programs, placental-derived cell therapies and commercial regenerative medicine products such as Biovance and Biovance 3L. Company news also covers clinical and coverage-related updates, operating and financial results, capital-structure actions and governance matters.
Recurring corporate updates include periodic-reporting status, Nasdaq compliance, tax-credit monetization, material agreements and shareholder matters. The company's disclosures also reference its common stock and warrants trading on Nasdaq under CELU and CELUW.
Celularity (Nasdaq: CELU) filed its Annual Report on Form 10-K for fiscal 2025 on May 1, 2026 and has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company said it completed strategic actions including an out-license of its biomaterials portfolio, a realignment of non-core personnel and a $13 million reduction in recorded liabilities. Management characterized the moves as sharpening strategic focus and strengthening the balance sheet to concentrate on core longevity and cell therapy platforms.
Celularity (Nasdaq: CELU) closed a transaction with NexGel on April 21, 2026, selling certain commercial and other assets from its biomaterials product portfolio.
Celularity received $13.3 million consideration: $8.3M cash at closing and a $5.0M convertible promissory note, plus up to $20.0M in milestone payments and royalties. The deal enabled retirement of nearly $13.0M of debt and aims to refocus resources on Celularity’s longevity therapeutic pipeline and manufacturing platform.
Celularity (Nasdaq: CELU) received a Nasdaq notice on April 16, 2026 for late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The notice says the company is not currently compliant with Nasdaq Listing Rule 5250(c)(1), but trading of CELU and CELUW continues. Celularity has 60 days to submit a compliance plan and may receive up to 180 days if Nasdaq accepts the plan. The company is working to file the Form 10-K and currently expects to do so in the coming weeks, but offers no assurance it will regain compliance.
Celularity (Nasdaq: CELU) reiterated its strategic commercialization partnership with NEXGEL (Nasdaq: NXGL) to license established biomaterial products and three 510(k) pathway programs. Celularity will be the exclusive manufacturer at its FDA-compliant Florham Park, New Jersey facility.
The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions, and aims to leverage renewed regulatory and reimbursement clarity for placental-derived biomaterials.
Celularity (NASDAQ: CELU) entered definitive agreements to grant an exclusive license for its commercial-stage placental-derived biomaterials and certain development-stage programs, with upfront and milestone payments totaling up to $35 million and potential future royalties.
Celularity will remain the exclusive manufacturer at its Florham Park FDA-compliant facility, creating ongoing manufacturing revenue, and will realign operations to focus on longevity-focused cellular therapeutics and capital efficiency.
Celularity (Nasdaq: CELU) received $12.2 million in net cash proceeds from selling approximately $126.3 million of New Jersey net operating losses and $1.9 million of unused New Jersey R&D tax credits on Feb 10, 2026.
The sale was completed through New Jersey’s Technology Business Tax Certificate Transfer Program administered by the NJEDA, providing non-dilutive, tax-free capital to strengthen liquidity and support commercial and GMP-level cell therapy programs.
Celularity (NASDAQ: CELU) commented on CMS’s December 24, 2025 withdrawal of skin substitute Local Coverage Determinations (LCDs) that had been due to take effect January 1, 2026.
CMS withdrew the LCDs while leaving in place a new Medicare payment rate of $127.28 per square centimeter for skin substitute applications effective January 1, 2026. The withdrawn LCDs would have kept Celularity’s Biovance and Biovance 3L eligible; CMS’s action removed Medicare coverage for 158 other skin substitute products. CEO Dr. Robert J. Hariri highlighted real-world evidence (including reduced steroid use in about half of treated patients) and cited Celularity’s scalable GMP/GTP manufacturing in Florham Park, NJ as compatible with the new reimbursement.
Celularity (Nasdaq: CELU) announced closing of financing transactions on Dec 22, 2025 that provided $10.0 million in gross proceeds with up to an additional $2.0 million available subject to closing conditions. The financing combines a $7.0 million senior secured term loan (first-priority lien on substantially all assets) and secured convertible notes with aggregate commitments up to $5.0 million, convertible at $1.66 per share. Celularity also issued five-year warrants for 3,707,657 Class A shares exercisable from June 19, 2026 at $2.00 per share. The company said proceeds will support operations, strategic initiatives and its longevity-focused platform.
Celularity (Nasdaq: CELU) entered binding term sheets for financing expected to provide up to $12.0 million in private capital to support priorities in longevity and preservation of human performance.
Under the term sheets, Celularity expects initial proceeds of $10.0 million, comprising a $7.0 million senior secured term loan with a first‑priority lien on substantially all assets and secured convertible notes of up to $5.0 million convertible at $1.66 per share. The company will also issue warrants equal to 33% of the as‑converted principal, exercisable after six months at $2.00 per share. Transactions are private placements and contingent on definitive agreements.
Celularity (Nasdaq: CELU) announced a strategic partnership with DefEYE, including an exclusive sublicense and pricing arrangement tied to Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity round.
DefEYE, formed from Verséa Ophthalmics leadership, reported ~70% sales growth in 2024 and plans to use funding to launch decellularized ophthalmic biologics including Biovance, Biovance 3L, Interfyl and related R&D. Celularity will be DefEYE’s exclusive contract manufacturer for the ophthalmic portfolio and retains the right to name one of five board members.